Lilly cancer drug with accelerated approval fails in confirmatory trial
A Phase III trial of Lartruvo, which won accelerated approval for soft-tissue sarcoma in 2016, failed to confirm an overall survival benefit.
Medtronic named best place to work in medical sales in 2015
MedReps.com surveyed 1,400 members of the site’s community, who currently work or recently worked in medical sales, to determine which companies are the best to work for overall. Best medical device company: Medtronic. Stryker and Johnson & Johnson ranked second and third. Best pharma company: Johnson & Johnson. Pfizer and Eli Lilly ranked second and […]
presented by
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Lilly’s rheumatoid arthritis drug using JAK inhibitors gets positive 2b results
Eli Lilly‘s (NYSE:LLY) rheumatoid arthritis treatment developed by drug developer Incyte (NASDAQ:INCY) using oral janus-associated kinases, or JAK, inhibitors, has produced positive phase 2b results, according to a company statement. The results were presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology. The randomized double-blind, placebo-controlled, dose-ranging study, known as JADA, involved […]